公开(公告)号：US20130296332A1

公开(公告)日：2013-11-07

申请号：US13932173

申请日：2013-07-01

Applicant: NOVARTIS AG

Inventor： Hans ALLGEIER ,  Yves AUBERSON ,  David CARCACHE ,  Philipp FLOERSHEIM ,  Christel GUIBOURDENCHE ,  Wolfgang FROESTL ,  Jörg KALLEN ,  Manuel KOLLER ,  Henri MATTES ,  Joachim NOZULAK ,  David ORAIN ,  Johanne RENAUD

IPC: C07D239/96 ,  C07C207/00 ,  C07C229/56 ,  C07D413/04 ,  C07D405/04 ,  C07D403/04 ,  C07C271/58

CPC classification number: C07D239/96 ,  C07C207/00 ,  C07C229/56 ,  C07C229/64 ,  C07C229/66 ,  C07C255/18 ,  C07C265/12 ,  C07C271/58 ,  C07D207/337 ,  C07D231/12 ,  C07D237/08 ,  C07D239/26 ,  C07D241/12 ,  C07D249/06 ,  C07D263/32 ,  C07D307/16 ,  C07D307/54 ,  C07D309/12 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D413/04

Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.

Abstract translation: 本发明涉及式（I）的1H-喹唑啉-2,4-二酮，其中R 1和R 2如说明书中所定义，其制备，作为药物的用途，以及含有它们的药物组合物。 此外，公开了用于制备式（I）化合物的中间体和包含式（I）化合物的组合。

公开(公告)号：US20230085472A1

公开(公告)日：2023-03-16

申请号：US17645071

申请日：2021-12-20

Applicant: Novartis AG

Inventor： David CARCACHE ,  Florian GRUBER ,  Danilo GUERINI ,  Martin GUNZENHAUSER ,  Richard HENG ,  Francesca PERRUCCIO ,  Oliver SIMIC ,  Carsten SPANKA

IPC: C07D401/14 ,  A61K45/06 ,  A61K31/4196 ,  A61K31/5377 ,  A61K31/454

Abstract: The present disclosure relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein R1 through R8 are as defined herein, and methods of making and using the same.

公开(公告)号：US20170305903A1

公开(公告)日：2017-10-26

申请号：US15581642

申请日：2017-04-28

Applicant: Novartis AG

Inventor： Dirk BEHNKE ,  David CARCACHE ,  Peter ERTL ,  Manuel KOLLER ,  David ORAIN

IPC: C07D471/04 ,  C07D519/00 ,  A61K31/551

Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.

公开(公告)号：US20240051954A1

公开(公告)日：2024-02-15

申请号：US18257318

申请日：2021-12-20

Applicant: NOVARTIS AG

Inventor： David CARCACHE ,  Florian GRUBER ,  Danilo GUERINI ,  Martin GUNZENHAUSER ,  Richard HENG ,  Francesca PERRUCCIO ,  Oliver SIMIC ,  Carsten SPANKA

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: The present disclosure relates to a compound of Formula (I): (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein Ring A, and R1 through R4 are as defined herein, and methods of making and using the same.